Kainomyx will lead the technical strategy for drug discovery and clinical phases, Aurigene will focus on developing scalable drug chemistry and Dr. Reddy’s will advise on the regulatory and market access processes.
The system includes a wearable, disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user.
The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb, Croatia.
